Inhibitory activities of selected Kampo formulations on human aldose reductase

BMC Complementary and Alternative Medicine

Kazuo Koike²  Masahiko Obayashi²  Wei Li²  Takahiro Fukazawa²  Chikako Ishikawa²  Toshihisa Onoda¹ 

[1] Toho University Sakura Medical Center, Shimoshidu 564-1, Sakura, Chiba 285-8741, Japan;Faculty of Pharmaceutical Sciences, Toho University, Miyama 2-2-1, Funabashi, Chiba 274-8510, Japan

关键词: Chotosan;    Diabetes complications;    Aldose reductase;    Kampo;   

Others  :  1085580
DOI  :  10.1186/1472-6882-14-435

 received in 2014-04-26, accepted in 2014-10-27,  发布年份 2014

【 摘 要 】

Background

Diabetes complications include various symptoms such as diabetic neuropathy and cognitive disorders. Aldose reductase (AR) is the rate-limiting enzyme of the polyol pathway and is one of the causal factors of diabetes complications. In this study, the bioactivities of eight selected Kampo formulations that are currently in clinical use for diabetes complications were assessed using human AR (hAR) inhibitory activity as the primary parameter to explore the possibilities of novel clinical applications of these formulations in the treatment of diabetes complications.

Methods

The hAR inhibitory activities of four Kampo formulations that are clinically used for diabetic neuropathy, four Kampo formulations that are used for cognitive disorders, and a total of 21 component crude drugs were measured. Furthermore, the hAR inhibitory activity of Glycyrrhizae Radix preparata was measured to determine the effect of frying, which is one of the specific processing of Glycyrrhizae Radix. hAR inhibitory activity was determined by measuring the rate of decline in the absorbance of NAPH at 340 nm using 0.5 mM NADPH, 10 mM D,L-glyceraldehyde, and 3.6 mU/mL hAR in phosphate buffer solution (0.2 M, pH 6.2).

Results

All of the Kampo formulations exhibited significant hAR inhibitory activity; Chotosan exhibited particularly strong activity. Among the 21 crude drugs tested, adequate inhibitory activities were found for the following, in descending order of activity: Glycyrrhizae Radix > Paeoniae Radix > Chrysanthemi Flos > Cinnamomi Cortex > Phellodendri Cortex > Uncariae Uncis cum Ramulus > Bupleuri Radix. Glycyrrhizae Radix preparata exhibited an inhibitory activity that was nearly identical to that of Glycyrrhizae Radix.

Conclusions

Despite their seemingly different treatment objectives, all of the Kampo formulations that are clinically used for diabetes complications demonstrated significant hAR inhibitory activity. This activity might underlie the characteristic multi-target effects of Kampo formulations. Although the overall effect of a Kampo formulation is certainly difficult to evaluate based on specific herbal medications or components, the approach as taken in this study might nonetheless contribute to further advancement in the development of new drugs via the review of proper usage and re-examination of the chemical compounds from a new perspective.

【 授权许可】

   
2014 Onoda et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Whiting DR, Guariguata L, Weil C, Shaw J: IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011, 94:311-321.
• [2]Forbes JM, Cooper ME: Mechanisms of diabetic complications. Physiol Rev 2013, 93(1):137-188.
• [3]Pasquier F, Boulogne A, Leys D, Fontaine P: Diabetes mellitus and dementia. Diabetes Metab 2006, 32:403-414.
• [4]Umegaki H, Hayashi T, Nomura H, Yanagawa M, Nonogaki Z, Nakshima H, Kuzuya M: Cognitive dysfunction: an emerging concept of a new diabetic complication in the elderly. Geriatr Gerontol Int 2013, 13(1):28-34.
• [5]Basta G: Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008, 196:9-21.
• [6]Yamagishi S, Matsui T: Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxidative Med Cell Longev 2010, 3(2):101-108.
• [7]Lin G, Brownsey RW, Macleod KM: Complex regulation of PKCβ2 and PDK-1/AKT by ROCK2 in diabetic heart. PLoS One 2014, 9(1):e86520.
• [8]Oates PJ: Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol 2002, 50:325-392.
• [9]Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, Aoki T, Etoh T, Hashimoto T, Naruse M, Sano H, Utsumi H, Nawata H: High glucose level and free fatty acid stimulate reactive oxygen species production through protein Kinase C–Dependent Activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000, 49:1939-1945.
• [10]Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR, Diabetic Retinopathy Clinical Research Network: A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007, 114(10):1860-1867.
• [11]Carswell CI, Goa KL: Losartan in diabetic nephropathy. Drugs 2003, 63(4):407-414.
• [12]Hotta N, Kawamori R, Atsumi Y, Baba M, Kishikawa H, Nakamura J, Oikawa S, Yamada N, Yasuda H, Shigeta Y, the ADCT Study Group: Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat. Diabet Med 2008, 25:818-825.
• [13]Hotta N, Sakamoto N, Shigeta Y, Kikkawa R, Goto Y: Clinical Investigation of Epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan. J Diabetes Complications 1996, 10:168-172.
• [14]Satoh K, Hayakawa T, Kase Y, Ishige A, Sasaki H, Nishikawa S, Kurosawa S, Yakabi K, Nakamura T: Mechanisms for contractile effect of dai-kenchu-to in isolated guinea pig ileum. Dig Dis Sci 2001, 46:250-256.
• [15]Sato Y, Uno T, Oyun K, Koide T, Tamagawa T, Bolin Q: Role of herbal medicine (Kampo formulations) on the prevention and treatment of diabetes and diabetic complications. J Trad Med 2006, 23:185-195.
• [16]Nakagawa T: Therapeutic potential of Keishi-bukuryo-gan on diabetic nephropathy. J Trad Med 2003, 21(1):7-16.
• [17]Suzuki T, Futami S, Igari Y, Matsumura N, Watanabe K, Nakano H, Oba K, Murata Y, Koibuchi H, Kigawa Y: A Chinese herbal medicine, choto-san, improves cognitive function and activities of daily living of patients with dementia: a double-blind, randomized, placebo-controlled study. J Am Geriatr Soc 2005, 53(12):2238-2240.
• [18]Iwasaki K, Satoh-Nakagawa T, Maruyama M, Monma Y, Nemoto M, Tomita N, Tanji H, Fujiwara H, Seki T, Fujii M, Arai H, Sasaki H: A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry 2005, 66(2):248-252.
• [19]Aida K, Shindo H, Tawata M, Onaya T: Inhibition of aldose reductase activities by kampo medicines. Planta Med 1987, 53(2):131-135.
• [20]Jung HA, Yoon NY, Kang SS, Kim YS, Choi JS: Inhibitory activities of prenylated flavonoids from Sophora flavescens against aldose reductase and generation of advanced glycation endproducts. J Pharm Pharmacol 2008, 60:1227-1236.
• [21]Yang Q, Goto H, Shimada Y, Kita T, Shibahara N, Terasawa K: Effects of Choto-san on hemorheological factors and vascular function in stroke-prone spontaneously hypertensive rats. Phytomedicine 2002, 9(2):93-98.
• [22]Badawy D, El-Bassossy HM, Fahmy A, Azhar A: Aldose reductase inhibitors zopolrestat and ferulic acid alleviate hypertension associated with diabetes: effect on vascular reactivity. Can J Physiol Pharmacol 2013, 91(2):101-107.
• [23]Aida K, Tawata M, Shindo H, Onaya T, Sasaki H, Yamaguchi T, Chin M, Mitsuhashi H: Isoliquiritigenin: a new aldose reductase inhibitor from glycyrrhizae radix. Planta Med 1990, 56(3):254-258.
• [24]Kawakami Z, Ikarashi Y, Kase Y: Isoliquiritigenin is a novel NMDA receptor antagonist in kampo medicine yokukansan. Cell Mol Neurobiol 2011, 31(8):1203-1212.
• [25]Tawata M, Aida K, Noguchi T, Ozaki Y, Kume S, Sasaki H, Chin M, Onaya T: Anti-platelet action of isoliquiritigenin, an aldose reductase inhibitor in licorice. Eur J Pharmacol 1992, 212:87-92.